- Home
- ATIP vs BIAF Comparison
ATIP vs BIAF Comparison
Compare ATIP & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIP
- BIAF
- Stock Information
- Founded
- ATIP 1996
- BIAF 2014
- Country
- ATIP United States
- BIAF United States
- Employees
- ATIP N/A
- BIAF N/A
- Industry
- ATIP Hospital/Nursing Management
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATIP Health Care
- BIAF Health Care
- Exchange
- ATIP Nasdaq
- BIAF Nasdaq
- Market Cap
- ATIP 26.0M
- BIAF 20.4M
- IPO Year
- ATIP N/A
- BIAF 2022
- Fundamental
- Price
- ATIP $6.24
- BIAF $2.13
- Analyst Decision
- ATIP
- BIAF Strong Buy
- Analyst Count
- ATIP 0
- BIAF 1
- Target Price
- ATIP N/A
- BIAF $6.00
- AVG Volume (30 Days)
- ATIP 7.9K
- BIAF 78.2K
- Earning Date
- ATIP 11-04-2024
- BIAF 11-12-2024
- Dividend Yield
- ATIP N/A
- BIAF N/A
- EPS Growth
- ATIP N/A
- BIAF N/A
- EPS
- ATIP N/A
- BIAF N/A
- Revenue
- ATIP $717,149,000.00
- BIAF $7,315,883.00
- Revenue This Year
- ATIP $10.99
- BIAF $302.41
- Revenue Next Year
- ATIP $5.98
- BIAF $15.00
- P/E Ratio
- ATIP N/A
- BIAF N/A
- Revenue Growth
- ATIP 11.00
- BIAF 30185.99
- 52 Week Low
- ATIP $3.92
- BIAF $1.15
- 52 Week High
- ATIP $8.48
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- ATIP 60.27
- BIAF 59.79
- Support Level
- ATIP $5.66
- BIAF $1.84
- Resistance Level
- ATIP $6.46
- BIAF $2.04
- Average True Range (ATR)
- ATIP 0.30
- BIAF 0.14
- MACD
- ATIP 0.01
- BIAF 0.02
- Stochastic Oscillator
- ATIP 72.50
- BIAF 90.57
About ATIP ATI Physical Therapy Inc.
ATI Physical Therapy Inc is a recognized outpatient physical therapy provider in the United States specializing in outpatient rehabilitation and adjacent healthcare services. It offer a variety of services within the clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.